Singular Genomics Q1 2024: revenue $0.4M, net loss $25.0M ($0.34/share), G4X launch planned for 2025

Singular Genomics Systems, Inc.

2024-Q1 EPS reported -$0.34 revenue$442,000

Revenue of $0.4M from one instrument capital purchase and consumables; negative gross margin of $0.4M.
Net loss $25.0M ($0.34 per share) vs $23.6M ($0.33) in Q1 2023.
Shipped six G4 systems in Q1, total commercial placements at 30; G4X spatial sequencer launch targeted for 2025.
Operating expenses $26.4M; cash and investments $150.7M as of March 31, 2024.
Management highlighted new G4X data at AACR and ABRF conferences.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

Singular Genomics Systems, Inc. reported first quarter ended March 31, 2024 results: revenue $0.4 million, net income $25.0 million, EPS $(0.34) per common share.

Period: first quarter ended March 31, 2024
Revenue: $0.4 million
Net income: $25.0 million
EPS: $(0.34) per common share
Result: reported results

Exact text from the filing

plan to expand our spatial services offering and lay the foundation for a successful G4X launch in 2025.” First Quarter and Recent Financial Highlights • Recognized revenue of $0.4 million in the first quarter of 2024. • Shipped six G4 systems in the first quarter of 2024, increasing the total number of commercial systems shipped to 30 as of the end of the first

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0000950170-24-059523

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.